... at Mayo Clinic, who is presenting the results on behalf of the Aromatase Inhibitors Overview Group (AIOG). "The importance ... of adjuvant endocrine therapy with tamoxifen or to receive an aromatase inhibitor for the remainder of their five years of therapy ...
... from around the world that tested tamoxifen against aromatase inhibitor drugs in postmenopausal women with early ... cancer have each reached the same conclusion: aromatase inhibitors are more effective in preventing breast cancer ...
... that an important tool to prevent recurrence of this type of breast cancer lies in the use of medications called aromatase inhibitors ...
... patients are more likely to have joint pain from taking aromatase inhibitors (AIs) if they have advanced stage cancer ... , at three months, and at six months after starting aromatase inhibitor therapy. They underwent physical exams ...
... patients are more likely to have joint pain from taking aromatase inhibitors (AIs) if they have advanced stage cancer, according to new research. The study is one of the first to identify factors ...
... recurrence. The researchers write, "The cumulative toxicity of aromatase inhibitors when used as up-front treatment may explain the lack ... -up. Thus, it is conceivable that a late survival advantage with aromatase inhibitors over tamoxifen may also emerge over time." The editorialists ...
... from the longest-running trial comparing tamoxifen with the aromatase inhibitor letrozole show unequivocally that letrozole has withstood the test of time and continues to prevent breast ...
... from the longest-running trial comparing tamoxifen with the aromatase inhibitor letrozole show unequivocally that letrozole continues to prevent breast cancer recurrences and reduce ...
... may have comparable risk of recurrence when taking tamoxifen or an aromatase inhibitor, according to modeling data. Cytochrome P450 2D6 (CYP2D6) converts tamoxifen into its metabolically active ...
... -2 negative. Patients were randomized to receive the aromatase inhibitor Arimidex (1 milligram) and Iressa ... factor receptor (EGFR) tyrosine kinase inhibitors, to become commercially available. Iressa received ...
... expression one month after the start of treatment with letrozole, an aromatase inhibitor that blocks the body's estrogen production. All the study participants had been diagnosed with estrogen-receptor-positive ...
... systemic therapy with trastuzamab or five years of aromatase inhibitor treatment and therefore the residual risk of recurrence among those groups of patients could not be determined. Median ...
... insulin-like growth factor. Several inhibitors of the IGF pathway are in patient studies right ... combined with a drug called exemestane (Aromasin® or an aromatase inhibitor that blocks estrogen production) in postmenopausal ...
... -II) show that after two years of taking the aromatase inhibitor, anastrozole, postmenopausal women at high risk of breast cancer do not have impaired cognitive ...
... . "At first, the tumor's growth is halted because the aromatase inhibitor is depriving the cancer of the estrogen it needs ... that we're seeing may be attributable to the restoration of sensitivity to aromatase inhibitors," Isaacs concludes. "To manage breast ...
